DonateRead the latest blogs from across our work within the secondary breast cancer community. From blogs on fundraising, research findings, information sharing, corporate achievements, community support and stories, celebrate with us as we work together to Make 2nds Count.
21st August 2022
Fulvestrant
Fulvestrant “the final overall survival results of the phase III SWOG S0226 trial show that the addition of first-line fulvestrant to anastrozole was associated with improved overall survival in postmenopausal women with hormone receptor–positive metastatic breast cancer.” https://ascopost.com/issues/may-25-2019/fulvestrantanastrozole-in-metastatic-breast-cancer/ What is Fulvestrant? Fulvestrant is a hormone treatment for post menopausal women with locally advanced or advanced breast cancer.